CV 301
Alternative Names: CEA-MUC-1-TRICOM Vaccine; CEA-MUC-1/TRICOM; CV-301; CVAC-301; Falimarev-inalimarev; Inalimarev-falimarev; PANVAC; PANVAC V/F; PANVAC-VFLatest Information Update: 23 Oct 2023
At a glance
- Originator Therion Biologics
- Developer BN ImmunoTherapeutics; Bristol-Myers Squibb; National Cancer Institute (USA); Therion Biologics
- Class Cancer vaccines; Membrane glycoproteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Pancreatic cancer
- Phase II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer
- Discontinued Breast cancer; Ovarian cancer
Most Recent Events
- 01 Aug 2023 Georgetown University terminates a phase I/II trial in Pancreatic cancer and Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC), due to lack of enrollment (NCT03376659)
- 10 Sep 2021 Efficacy data from a phase II trial in Bladder cancer presented at the 116th Annual Meeting of the American Urological Association (AUA-2021)
- 19 Feb 2021 Phase II development in Prostate cancer (Combination therapy, Metastatic disease) is still ongoing in USA (SC) (NCT03315871)